Publicaciones en colaboración con investigadores/as de Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer (7)

2024

  1. Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling

    Haematologica, Vol. 109, Núm. 3, pp. 877-887

2023

  1. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

    Blood Advances, Vol. 7, Núm. 11, pp. 2645-2655

2022

  1. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

    Blood, Vol. 140, Núm. 26, pp. 2773-2787

  2. Expression of p53 protein isoforms predicts survival in patients with multiple myeloma

    American Journal of Hematology, Vol. 97, Núm. 6, pp. 700-710

  3. TCL-318 Evaluation of the Antitumor Activity of Amiloride in Peripheral T-Cell Lymphomas Using In-Vitro Models

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S399

  4. Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome

    British Journal of Haematology, Vol. 199, Núm. 3, pp. 344-354

2021

  1. Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications

    Cells, Vol. 10, Núm. 2